Emeric Frejafon
Research Subjects
Emeric Frejafon has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Adriele Prina-Mello
Laboratory for Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, Trinity College Dublin, Dublin, Ireland
1 shared publication - Albert Duschl
Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria
1 shared publication - Alfonso Arevalillo
TECNALIA, Basque Research and Technology Alliance (BRTA), 20730 Azpeitia, Spain
1 shared publication - Anna-Kaisa Viitanen
Finnish Institute of Occupational Health Helsinki Finland
1 shared publication - Anthony Bochon
JurisLab, Centre de droit privé, Université Libre de Bruxelles, Avenue F. Roosevelt 50, CP 137, 1050 Bruxelles, Belgium
1 shared publication - Bastien Caillard
European Risk Management Institute (EU-VRi), Fangelsbachstr. 14, 70178 Stuttgart, Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 12 June 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (9) , 2578-2588
Toward an international standardisation roadmap for nanomedicine
The French National Metrology Institute (LNE) initiated a series of events to identify priorities for test methods and their harmonisation that directly address regulatory needs in Nanomedicine. One of these workshops entitled “The International Standardisation Roadmap for Nanomedicine” held in October 2023 (Paris, France) brought together key experts in the characterisation of nanomedicines and medical products containing nanomaterials, including the Joint Research Centre of the European Commission, SINTEF Industry and the metrology institutes of France, the UK, the USA and Canada, two flagship initiatives of the European Commission (PHOENIX and SAFE-n-MEDTECH Open Innovation Test Beds), representatives of a working party on mRNA vaccines at the European Directorate for the Quality of Medicines (EDQM) and members of international standardisation and pre-normative organisations (including CEN, ISO, ASTM, VAMAS). Two take-home message came out from the discussion. First, developing standard test methods and Reference Materials (RMs) for nanomedicines is a key priority for the European Commission and various stakeholders. Furthermore, there was a unanimous recognition of the need for a unified approach between standardisation committees, regulators and the nanomedicine community. At the USA, Canadian and European level, examples of success stories and of future initiative have been discussed. Future perspectives include the creation of a dedicated Working Group under CEN/TC 352 to consolidate efforts and develop a nanomedicine standardisation roadmap. Graphical Abstract
- 12 June 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (9) , 2578-2588
Top Cited PapersOpen AccessToward an international standardisation roadmap for nanomedicine
The French National Metrology Institute (LNE) initiated a series of events to identify priorities for test methods and their harmonisation that directly address regulatory needs in Nanomedicine. One of these workshops entitled “The International Standardisation Roadmap for Nanomedicine” held in October 2023 (Paris, France) brought together key experts in the characterisation of nanomedicines and medical products containing nanomaterials, including the Joint Research Centre of the European Commission, SINTEF Industry and the metrology institutes of France, the UK, the USA and Canada, two flagship initiatives of the European Commission (PHOENIX and SAFE-n-MEDTECH Open Innovation Test Beds), representatives of a working party on mRNA vaccines at the European Directorate for the Quality of Medicines (EDQM) and members of international standardisation and pre-normative organisations (including CEN, ISO, ASTM, VAMAS). Two take-home message came out from the discussion. First, developing standard test methods and Reference Materials (RMs) for nanomedicines is a key priority for the European Commission and various stakeholders. Furthermore, there was a unanimous recognition of the need for a unified approach between standardisation committees, regulators and the nanomedicine community. At the USA, Canadian and European level, examples of success stories and of future initiative have been discussed. Future perspectives include the creation of a dedicated Working Group under CEN/TC 352 to consolidate efforts and develop a nanomedicine standardisation roadmap. Graphical Abstract
- 1 July 2021
- Published by Elsevier in NanoImpact
- Vol. 23, 100337
Blueprint for a self-sustained European Centre for service provision in safe and sustainable innovation for nanotechnology
- 1 July 2021
- Published by Elsevier in NanoImpact
- Vol. 23, 100337
Blueprint for a self-sustained European Centre for service provision in safe and sustainable innovation for nanotechnology